EAST BRUNSWICK, N.J., Oct. 28 Savient Pharmaceuticals, Inc. announced today that the company will release financial results for the third quarter 2009 following the close of the market on Wednesday, November 4, 2009.
To participate by telephone, please dial 888-397-5354 from the U.S. or 719-457-2615 for international callers. The conference identification number is 6621643. The live and archived webcast can be accessed on the investor relations section of the Savient Web site at www.savient.com. Please log on to Savient’s Web site 15 minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.
About Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA(TM) (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.
CONTACT: Mary Coleman, Savient Pharmaceuticals, Inc., +1-732-418-9300,
information@savient.com; Susan Neath, Burns McClellan, +1-212-213-0006,
sneath@burnsmc.com
Web site: http://www.savient.com/
